YOLFTbeta
Biomm S.A

Biomm S.A

BIOM3 · SA · Healthcare / Biotechnology

6.00BRL+0.54 (+9.89%)

Price History

Full chart

Market Stats

Previous Close5.46
Open5.54
Day Range5.54 – 6.00
52-Week Range4.82 – 10.39
Volume15.20K
Market Cap882.70M
P/E (TTM)28.04
Forward P/E0.00
EPS0.23
Dividend Yield0.00%
Beta0.46
50-Day Avg6.22
200-Day Avg6.70

About

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina. The company was incorporated in 2001 and is based in Nova Lima, Brazil.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Guilherme Maradei
  • Employees0
  • Headquarters705 ? Lagoa dos Ingleses, Nova Lima, MG, Brazil, 34018-000, Brazil
  • Websitehttps://www.biomm.com

Leadership

  • Mr. Guilherme MaradeiCEO & Member of Executive Board
  • Mr. Marclo Safadi AlvaresChief Financial & IR Officer and Member of Executive Board
  • Mr. Francisco Carlos Marques de FreitasChief Technology Officer & Member of the Executive Board
  • Mr. Francisco Rafael Costa Jr.Commercial Director & Member of Executive Board
  • Mr. Luciano da Silva MachadoChief Operating Officer & Member of Executive Board
  • Ms. Nayara Rodrigues de Souza CruzAccountant
  • Mr. Alexandre Bernardes GoncalvesMember of Executive Board & Commercial Director

Financials

Income Statement

Currency: BRL2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.81M6.64M2.00M3.02M608.00K877.00K231.00K-0000103.00K1.57M8.94M58.67M107.09M104.95M118.19M142.91M269.30M
Growth (%)-+136.56%-69.98%+51.23%-79.85%+44.24%-73.66%------+1420.39%+471.14%+555.95%+82.54%-1.99%+12.62%+20.91%+88.45%
Cost of Revenue1.81M2.29M1.53M2.09M218.00K436.00K231.00K-164.00K307.00K342.00K420.00K67.00K1.32M8.42M44.73M80.16M88.96M94.94M125.02M187.53M
Gross Profit1.00M4.35M465.00K928.00K390.00K441.00K---164.00K0-342.00K-420.00K36.00K245.00K521.00K13.94M26.93M16.00M23.26M17.88M81.77M
Gross Margin35.60%65.46%23.31%30.76%64.14%50.29%------34.95%15.64%5.83%23.75%25.15%15.24%19.68%12.51%30.36%
Operating Expense4.63M4.10M5.44M5.81M3.90M4.68M--11.19M16.75M21.90M30.21M35.46M36.92M53.13M69.37M92.58M102.23M95.78M99.09M76.94M
Operating Income-3.63M254.00K-4.97M-4.88M-3.51M-4.24M-4.12M-11.84M-11.36M-16.75M-22.24M-30.63M-35.42M-36.67M-52.61M-55.44M-65.65M-86.24M-72.53M-81.21M4.83M
Operating Margin-129.41%3.82%-249.17%-161.75%-577.30%-483.69%-1784.85%------34389.32%-2341.89%-588.22%-94.49%-61.30%-82.17%-61.36%-56.83%1.79%
EBITDA-3.19M254.00K-4.97M-3.87M-3.33M-4.05M-4.22M-5.56M-15.39M-10.46M22.58M-43.09M-31.44M-30.14M-40.44M-48.65M-53.76M-66.66M-56.19M-53.10M13.39M
EBITDA Margin-113.56%3.82%-249.17%-128.31%-547.20%-462.14%-1825.11%------30521.36%-1924.65%-452.12%-82.93%-50.20%-63.52%-47.54%-37.16%4.97%
Net Income-4.00M6.00K-5.32M-7.41M-5.73M-4.27M-4.67M-14.14M-10.06M-12.71M8.28M-45.61M-38.13M-42.56M-55.81M-70.77M-80.26M-92.56M-81.14M-77.24M-6.69M
Net Income Margin-142.58%0.09%-266.57%-245.74%-941.94%-487.23%-2023.81%------37017.48%-2717.88%-624.02%-120.62%-74.95%-88.19%-68.65%-54.05%-2.48%
R&D--------------4.38M4.46M-----
R&D as % of Total Revenue--------------48.92%7.59%-----
Interest Expense815.00K2.03M2.46M4.36M2.21M31.00K636.00K1.25M1.52M1.75M5.37M6.00M16.25M19.28M12.63M14.12M17.32M16.78M14.95M12.87M13.13M
Interest Expense % of Total Revenue29.01%30.59%123.11%144.35%362.99%3.53%275.32%-----15771.84%1231.16%141.20%24.07%16.17%15.99%12.65%9.01%4.88%

Balance Sheet

Currency: BRL2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.40M15.71M11.16M9.71M12.17M10.66M4.91M11.30M7.01M138.08M179.56M229.67M237.38M262.39M305.68M388.77M434.97M369.83M405.09M344.70M465.66M524.23M
Total Liabilities5.31M12.63M8.07M11.94M24.39M10.67M8.97M20.06M29.00M29.14M72.46M114.55M171.46M203.09M199.59M235.21M243.49M258.25M245.98M221.76M202.88M210.72M
Total Equity7.09M3.08M3.09M-2.23M-12.22M-15.00K-4.06M-8.76M-22.00M108.94M107.10M115.13M65.93M59.30M106.09M153.56M191.48M111.59M159.11M122.94M262.78M313.51M
Cash-3.10M449.00K130.00K271.00K6.05M124.00K2.68M546.00K20.68M7.48M24.99M7.83M8.63M20.98M30.07M57.40M31.37M75.93M26.00M77.62M22.30M
Total Debt305.00K849.00K5.32M10.38M21.67M--16.91M24.98M15.62M62.41M83.05M117.24M154.97M147.32M155.59M188.32M184.15M172.28M153.60M121.38M96.60M
Net Debt305.00K849.00K4.87M10.25M21.40M-6.05M-124.00K14.23M24.43M-5.06M54.93M58.06M109.41M146.34M126.34M125.52M130.92M152.78M96.35M127.60M43.76M74.30M

Cash Flow

Currency: BRL2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.07M--5.71M-7.50M-4.64M-1.78M-7.23M-10.51M-19.78M-13.90M-38.28M-54.41M-44.12M-77.61M-96.87M-93.78M-63.00M-74.78M-91.84M-111.92M
Investing Cash Flow-269.00K378.00K-3.19M-267.00K-501.00K-1.03M-915.00K-102.88M-48.84M-4.87M-21.67M-2.16M-27.35M-20.52M-6.84M61.49M-6.16M-2.86M-37.99M22.42M
Financing Cash Flow---9.05M13.54M-786.00K5.37M6.01M133.54M55.50M36.47M42.77M57.38M80.48M107.40M129.22M7.42M113.79M25.56M180.87M34.17M
Capital Expenditure102.00K212.00K54.00K0267.00K501.00K1.03M915.00K31.78M23.54M34.31M63.15M5.81M909.00K7.35M4.63M7.44M5.44M6.22M19.16M26.59M
Free Cash Flow----5.71M-5.58M-5.14M-2.81M-8.14M-42.29M-40.02M-48.21M-101.43M-60.21M-47.09M-88.20M-99.88M-101.23M-68.44M-81.01M-111.00M-138.50M
FCF to OCF---100.00%74.40%110.80%157.80%112.66%402.44%202.31%346.88%264.97%110.67%106.74%113.65%103.10%107.94%108.63%108.32%120.86%123.76%

Earnings

Report DateMar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022
EPS Estimate--------------------------------------
EPS Actual-0.12-0.26-0.10-0.06-0.18-0.18-0.00-0.040.06-0.180.290.09-0.34-0.46-0.28-0.34-0.32-0.30-0.26-0.20-0.30-0.28-0.21-0.24-0.33-0.28-0.31-0.23-0.32-0.23-0.20-0.40-0.29-0.20-0.25-0.45-0.29-0.33
Surprise--------------------------------------
Timing--------------------------------------

Key Statistics & Ratios

Market Cap882.70M
Enterprise Value953.57M
Trailing P/E28.04
Forward P/E0.00
PEG Ratio0.00
Price / Sales2.30
Price / Book2.63
EPS0.23
Book Value2.38
Revenue (TTM)384.42M
Gross Profit (TTM)138.63M
EBITDA50.10M
Profit Margin7.89%
Operating Margin10.00%
Return on Equity10.77%
Return on Assets4.89%
Shares Outstanding136.85M
Shares Float20.07M
Beta0.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20132×
0.00Dec 18, 20130.00Apr 30, 2013
20121×
0.00Apr 27, 2012
20101×
0.00Apr 29, 2010
20071×
3.60Apr 27, 2007
20061×
2.15Apr 27, 2006
20053×
4.30Dec 5, 200517.65Aug 22, 20055.93Apr 28, 2005

Stock Splits

  • Mar 21, 20133:1